Screening for familial ovarian cancer: A ray of hope and a light to steer

Journal of Clinical Oncology

Volumn 31, Issue 1, 2013, Pages 8-10

  Long, Kara C ^a   Kauff, Noah D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; EDITORIAL; FALSE POSITIVE RESULT; FAMILIAL CANCER; FAMILIAL OVARIAN CANCER; FEMALE; GENETIC RISK; HUMAN; OVARY CANCER; PATIENT COUNSELING; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; UTERINE TUBE CARCINOMA;

EARLY DETECTION OF CANCER; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASS SCREENING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 84871815350     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.4678     Document Type: Editorial

References (24)

1. Bast RC Jr, Feeney M, Lazarus H, et al: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331-1337, 1981
2. Campbell S, Goessens L, Goswamy R, et al: Real-time ultrasonography for determination of ovarian morphology and volume: A possible early screening test for ovarian cancer? Lancet 1:425-426, 1982
3. Mulley AG: Health maintenance and the role of screening, in Goroll AH, Mulley AG: Primary Care Medicine: Office Evaluation and Management of the Adult Patient (ed 6). Philadelphia, PA, Wolters Kluwer/Lippincott Williams & Wilkins, 2009
4. Partridge E, Kreimer AR, Greenlee RT, et al: Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 113:775-782, 2009
5. Buys SS, Partridge E, Black A, et al: Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305:2295-2303, 2011
6. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003
7. Hogg R, Friedlander M: Biology of epithelial ovarian cancer: Implications for screening women at high genetic risk. J Clin Oncol 22:1315-1327, 2004
8. Kurman RJ, Visvanathan K, Roden R, et al: Early detection and treatment of ovarian cancer: Shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 198:351-356, 2008
9. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al: Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer. J Clin Oncol 26:20-25, 2008
10. Gallagher DJ, Konner JA, Bell-McGuinn KM, et al: Survival in epithelial ovarian cancer: A multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol 22:1127-1132, 2011
11. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011
12. Hyman DM, Zhou Q, Iasonos A, et al: Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118:3703-3709, 2012
13. Bolton KL, Chenevix-Trench G, Goh C, et al: Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307:382-390, 2012
14. Rosenthal AN, Fraser L, Manchanda R, et al: Results of annual screening in phase I of the United Kingdom Familial Ovarian Cancer Screening Study highlight the need for strict adherence to screening schedule. J Clin Oncol 31:49-57, 2013
15. Skates SJ, Menon U, MacDonald N, et al: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 21:206s-210s, 2003 (suppl 10)
16. Kauff ND, Mitra N, Robson ME, et al: Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst 97:1382-1384, 2005
17. Metcalfe KA, Finch A, Poll A, et al: Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer 100:421-425, 2009
18. Surveillance, Epidemiology, and End Results (SEER) Program: SEER*Stat Database: Incidence - SEER 18 Regs Research Data 2011 Sub (2000-2009), 2011. http://seer.cancer.gov/data/metadata.html
19. Kauff ND: Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer? J Clin Oncol 26:9-10, 2008
20. Long KC, Kauff ND: Hereditary ovarian cancer: Recent molecular insights and their impact on screening strategies. Curr Opin Oncol 23:526-530, 2011
21. Hyman DM, Spriggs DR: Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer. JAMA 307:408-410, 2012
22. Greene MH, Piedmonte M, Alberts D, et al: A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: Design and baseline characteristics - A Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev 17:594-604, 2008
23. American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins - Gynecology, ACOG Committee on Genetics, et al: ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113:957-966, 2009
24. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2012. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp